D-0747-2022 Class III Terminated

Recalled by Advanced Accelerator Applications USA, Inc. — Millburn, NJ

FDA drug recall D-0747-2022 was initiated by Advanced Accelerator Applications USA, Inc. on Mar 18, 2022 and is designated Class III. Reason for recall: Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies. The recall status is terminated (terminated Jan 4, 2023). Affected quantity: 14,089 kits.

Recall details

Product Type
Drugs
Report Date
Apr 13, 2022
Initiation Date
Mar 18, 2022
Termination Date
Jan 4, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14,089 kits

Product description

NETSPOT (kit for the preparation of Ga 68 dotatate injection) 40 mcg dotatate, kit contains Vial 1 (Reaction vial with lyophilized powder), 1 Single dose vial, consisting of 40 mcg of dotate, 5 mcg of 1,10-phenanthroline, 6 mcg of Gentisic acid, 20 mg of D-Mannitol, and Nitrogen; and Vial 2, 1 Single dose vial of reaction buffer, Rx Only, Manufactured for: Advanced Accelerator Applications USA, Inc., by: Gipharma S.r.l., Strada Crescentino snc, 13040 Saluggia (Vc), Italy, NDC 69488-001-40

Reason for recall

Subpotent Drug: low out-of-specification results for Vial 1 assay obtained during stability studies.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot # (Vial 1)/kit: (F03221004 vial) in kit PG1921014, PG1921015, Exp 16-Mar-2022; (F03221005 vial) in kit PG1921016, PG1921017, Exp 18-Mar-2022; (F03221006 vial) in kit PG1921018, PG1921019, Exp 11-May-2022; (F03221007 vial) in kit PG1921020, PG1921021, Exp 04-Aug-2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0747-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0747-2022. Report a data issue: hello@regdatalab.com.